Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pipamperone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ANT01 (pipamperone dihydrochlorideshows) a unique combined high BLOCKING affinity toward the human serotonin 2A and dopamine 4 receptor, which being invetigated for for Major Depressive Disorder.
Brand Name : ANT-01
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 05, 2023
Lead Product(s) : Pipamperone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pipamperone,Undisclosed
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Johnson & Johnson
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The data for ANT-01 (pipamperone dihydrochloride) showed an improvement in the ability to feel pleasure and in cognitive function, which has not been demonstrated by any other antidepressant molecule.
Brand Name : ANT-01
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 05, 2022
Lead Product(s) : Pipamperone,Undisclosed
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Johnson & Johnson
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?